Onco Actu du 9 avril 2020

	1.1 BIOLOGIE - GÉNOME
Cancer Mutation in Dual Role [University of Freiburg] Researchers show that an oncogenic mutation in leukemia cells also promotes inflammations in the body.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
New Prognostic Tool Helps Leukemia Patients Plan for Cancer Treatment [ASH] First validated prognostic score offers valuable insights for patients advised to ‘watch and wait’.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction [Genome Web] The team envisions developing a non-invasive liquid biopsy assay to guide targeted treatment for mCRPC patients.
	4.10 DÉP., DIAG. & PRONO. - POUMON
MIT Team Develops Protease-Based Test for Early Detection of Lung Cancer [Genome Web] While the method has shown promise in mouse models, it is still several years away from potential use as a diagnostic tool, but if successful, it could aid early detection of lung cancer by, for instance, helping evaluate indeterminate nodules detected during computed tomography-based lung cancer screening.
	4.12 BIOPSIES LIQUIDES
Esophageal Cancer Case Study Suggests Utility as Clinicians Explore Expanded Uses for Liquid Biopsy [Genome Web] Among other takeaways, the investigators reported that the patient's cancer recurrence was evident in ctDNA results 174 days before the patient showed elevation of the protein biomarker CEA, and 350 days before a liver metastasis could be detected on radiographic imaging.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Pancreatic cancer blocked by disrupting cellular pH balance [Sanford Burnham Prebys] The study, published in Cancer Discovery, reports how depleting an ion transport protein lowers the pH to a point that compromises pancreatic cancer cell growth.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings [Fierce Pharma] The move sets Opdivo and Yervoy up for an FDA verdict by August 6, which could follow closely on the heels of another potential nod. The agency is currently evaluating the drugs without chemo in the same patient population, and after applying a priority tag to that filing, too, it set a decision date for May 15.
Merck and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma [Merck] Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results.
FDA's new Keytruda review is a step for genetic medicine, immunotherapy [Biopharma Dive] If approved by the FDA's June 16 deadline, it would be the second so-called tissue agnostic approval for Keytruda.
	5.2.6 PHARMA - BIOTECH
Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs [Xconomy] Tango now has a pipeline of five programs, the most advanced of which is being developed to address the loss of a tumor suppressor gene.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy [Pfizer] BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated metastatic CRC with a BRAFV600E mutation.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Coronavirus and the Cancer Patient [NY Times] My patients’ immune systems are so exquisitely fragile that it doesn’t take much to catch an infection that could kill them.
Between Scylla and Charybdis — Oncologic Decision Making in the Time of Covid-19 [NEJM] To survive SARS-CoV-2 only to then succumb to an undertreated cancer would be a Pyrrhic victory. The acuteness of infection and the chronicity of malignancy are the Scylla and Charybdis between which oncologists and their patients must now chart a very cautious course indeed.